Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Genetic Analysis Provides Insights into How Human Growth Is Linked to OA

Lara C. Pullen, PhD  |  July 31, 2017

The ancestral allele (clade A) dominates in Africa, whereas the same GROW1 mutation (clade B) can be found in Neandertals, Denisovans and modern Eurasians. This distribution raises the possibility of independent selection of ancestral standing variants. In the case of Eurasians, the allele is found near the center of a ~130-kb haplotype that runs from the GDF5 5’ untranslated region through the downstream region that controls limb length in mice. The resulting decreased bone growth, although increasing the risk for OA, may provide an associated selective advantage in mating, sexual selection, energetic control, thermoregulation or decreased risk of hip fracture.


Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Capellini TD, Chen H, Cao J, et al. Ancient selection for derived alleles at a GDF5 enhancer influencing human growth and osteoarthritis risk. Nat Genet. 2017 Jul 3. doi: 10.1038/ng.3911. [Epub ahead of print]

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bone growthgeneGenetic researchgeneticsgrowthOsteoarthritisosteoarthritis (OA)

Related Articles

    Hip-Resurfacing Arthroplasty an Alternative to Total Hip Replacement

    December 1, 2014

    Resurfacing procedure preserves bone, lasts longer, allows patients higher level of functionality

    Rheumatology Case Report: Deep Vein Thrombosis Detected by Point-of-Care Ultrasound

    April 18, 2017

    Case A 46-year-old Caucasian female presented to the outpatient rheumatology clinic where she had been followed for several years. Her chief complaint was pain in her right knee, posterior right thigh and right hip that had begun gradually over the previous three weeks. Her past medical history was significant for rheumatoid arthritis (RA), obesity and…

    Basics of Biologic Joint Reconstruction

    April 6, 2012

    For young patients especially, this can delay knee replacement and provide better outcomes.

    How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

    How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

    July 13, 2016

    The mechanistic link between human leukocyte antigen B27 (HLA-B27) and ankylosing spondylitis (AS) is one of the great enigmas in rheumatology. The introduction of biological therapies that target tumor necrosis factor (TNF) or the interleukin (IL) 23/IL-17A axis has had a major impact on the quality of life for many patients with AS, and one…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences